Lexeo Therapeutics announced it will present multiple new data sets on its cardiac gene therapy programs and advanced AAV manufacturing platform at the 29th ASGCT Annual Meeting in May 2026. Highlights include progress in treating Friedreich ataxia cardiomyopathy and TNNI3 cardiomyopathy using novel gene therapies, supported by preclinical and clinical data. These presentations underscore Lexeo's commitment to innovative cardiovascular genetic treatments and its potential impact on patient care. The company is advancing several gene therapy candidates, including LX2006, which is in clinical trials and has received multiple FDA designations.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
Crypto investigator ZachXBT criticized all current hardware wallets as insecure and unreliable for signing transactions or storing significant funds. He highlighted Ledger as particularly problematic due to frequent updates that disrupt basic functio...
DMG Blockchain Solutions announced two strategic investments: one in MeetAmi Innovations, a Canadian fintech offering digital asset wealth management platforms, and another in Atomic47 Labs, an AI company focused on secure, sovereign AI infrastructur...
